Pathios Therapeutics: Innovating Cancer Immunotherapy with GPR65 Inhibition
Pathios Therapeutics, based in Oxford, UK, recently announced the successful closure of their Series B funding, raising a significant $25 million. The funding round was supported by prominent investors such as Bristol Myers Squibb, as well as existing backers like Canaan and Brandon Capital. With this infusion of capital, the company plans to further advance their innovative approach to cancer immunotherapy, which centers around the inhibition of GPR65, a new target associated with various immunologically-mediated diseases.
The leadership of Pathios Therapeutics is comprised of seasoned professionals in the field, with Tom McCarthy, Ph.
.D., serving as co-founder and executive chair, and Stuart Hughes, Ph.D., at the helm as chief executive officer. Together, they are dedicated to translating cutting-edge scientific discoveries into transformative medicines. The founding team of Pathios includes individuals with diverse backgrounds in biotechnology, pharmaceuticals, entrepreneurship, and clinical practice, positioning the company well to drive forward advancements in cancer treatment.
At the core of Pathios' research and development efforts is the focus on developing small molecule inhibitors targeting the pH-sensing G protein-coupled receptor GPR65. By counteracting the immunosuppressive effects mediated by GPR65, particularly in tumor associated macrophages influenced by the acidic microenvironment of tumors, Pathios aims to make significant strides in enhancing the body's immune response against cancer. This innovative approach holds promise for addressing a critical unmet need in cancer therapy and underscores Pathios' commitment to pioneering solutions with the potential to make a real impact on patient outcomes.
They've invested in Pathios Therapeutics
Get to know these Biotech investors
Click here for a full list of 6,481+ startup investors in the UK